https://www.selleckchem.com/pr....oducts/GSK690693.htm
Purpose To study the levels of complement activation in different disease stages of AMD and the influence of genetic polymorphisms in complement genes. Methods We included 797 patients with AMD and 945 controls from the European Genetic Database. Patients were grouped into five AMD stages early AMD, intermediate AMD, central geographic atrophy, active choroidal neovascularization or inactive choroidal neovascularization. Differences in complement activation, as defined by the systemic C3d/C3 ratio, between AMD stages were evaluated us